Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Express Scripts
Merck
Baxter
Medtronic

Last Updated: February 18, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,539,262


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,539,262 protect, and when does it expire?

Patent 9,539,262 protects XELPROS and is included in one NDA.

This patent has nineteen patent family members in seventeen countries.

Summary for Patent: 9,539,262
Title:Ophthalmic composition comprising a prostaglandin
Abstract: The present invention relates to a pharmaceutical composition suitable for ophthalmic use comprising one or more prostaglandin derivatives or salts, a stabilizing amount of polyethylene glycol hydroxystearate and pharmaceutically acceptable vehicle.
Inventor(s): Khopade; Ajay Jaysingh (Baroda, IN), Halder; Arindam (Baroda, IN), Bhowmick; Subhas Balaram (Baroda, IN)
Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (Mumbai, IN)
Application Number:14/691,167
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,539,262

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sun Pharma Global XELPROS latanoprost EMULSION;OPHTHALMIC 206185-001 Sep 12, 2018 RX Yes Yes   Start Trial   Start Trial REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,539,262

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
India2061/MUM/2007Oct 16, 2007

International Family Members for US Patent 9,539,262

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008344909   Start Trial
Brazil PI0818459   Start Trial
Canada 2702478   Start Trial
China 101835473   Start Trial
Colombia 6270384   Start Trial
Eurasian Patent Organization 201070483   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
McKinsey
Baxter
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.